SCOPUS 정보 검색 플랫폼

Cancer Biology and Therapy

Volumn 15, Issue 10, 2014, Pages 1299-1300

A potential immunologic agent in the treatment of metastatic castration-resistant prostate cancer

(3) Kittai, Adam a Meshikhes, Mariam b Aragon Ching, Jeanny B a

a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER (United States)

b GEORGE WASHINGTON UNIVERSITY (United States)

Author keywords

Ipilimumab; Prostate cancer

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; DOCETAXEL; IPILIMUMAB; PLACEBO; SIPULEUCEL T; CANCER VACCINE; INTERCELLULAR ADHESION MOLECULE 1; TISSUE EXTRACT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; FOOD AND DRUG ADMINISTRATION; GLEASON SCORE; HUMAN; IMMUNE RESPONSE; MELANOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; TREATMENT RESPONSE; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY; INTERCELLULAR ADHESION MOLECULE-1; MALE; PROSTATIC NEOPLASMS; TISSUE EXTRACTS;

EID: 84908464295 PISSN: 15384047 EISSN: 15558576 Source Type: Journal
DOI: 10.4161/cbt.29928 Document Type: Article

Times cited : (6)

References (5)

1
- 77955066199
- Sipuleucel-T immunotherapy for castration-resistant prostate cancer
- PMID: 20818862
- Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22; PMID: 20818862; http://dx.doi.org/10.1056/NEJMoa1001294
- (2010) N Engl J Med , vol.363 , pp. 411-422
- Kantoff, P.W.¹ Higano, C.S.² Shore, N.D.³ Berger, E.R.⁴ Small, E.J.⁵ Penson, D.F.⁶ Redfern, C.H.⁷ Ferrari, A.C.⁸ Dreicer, R.⁹ Sims, R.B.¹⁰

2
- 84901641673
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial
- PMID: 24831977
- Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, et al. CA184-043 Investigators. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15: 700-12; PMID: 24831977; http://dx.doi.org/10.1016/S1470-2045(14)70189-5
- (2014) Lancet Oncol , vol.15 , pp. 700-712
- Kwon, E.D.¹ Drake, C.G.² Scher, H.I.³ Fizazi, K.⁴ Bossi, A.⁵ Van Den Eertwegh, A.J.⁶ Krainer, M.⁷ Houede, N.⁸ Santos, R.⁹ Mahammedi, H.¹⁰

3
- 77954801079
- Improved survival with ipilimumab in patients with metastatic melanoma
- PMID: 20525992
- Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23; PMID: 20525992; http://dx.doi.org/10.1056/NEJMoa1003466
- (2010) N Engl J Med , vol.363 , pp. 711-723
- Hodi, F.S.¹ O'Day, S.J.² McDermott, D.F.³ Weber, R.W.⁴ Sosman, J.A.⁵ Haanen, J.B.⁶ Gonzalez, R.⁷ Robert, C.⁸ Schadendorf, D.⁹ Hassel, J.C.¹⁰

4
- 84865812216
- NCT01057810
- NCT01057810. Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer.
- Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

5
- 79959572215
- From clinical trials to clinical practice: Therapeutic cancer vaccines for the treatment of prostate cancer
- PMID: 21692697
- Madan RA, Aragon-Ching JB, Gulley JL, Dahut WL. From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Expert Rev Vaccines 2011; 10: 743-53; PMID: 21692697; http://dx.doi.org/10.1586/erv.11.70
- (2011) Expert Rev Vaccines , vol.10 , pp. 743-753
- Madan, R.A.¹ Aragon-Ching, J.B.² Gulley, J.L.³ Dahut, W.L.⁴

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.